ASCO GU 2022 | American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium

Updated: Feb 19

JANSSEN

Niraparib, abiraterone acetate, prednisone combination

Janssen announced the initial results from the Phase 3 MAGNITUDE study evaluating the combination of niraparib, abiraterone acetate, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). The patients might or not have the homologous recombination repair (HRR) gene mutation.

MAGNITUDE is a randomized, double-blind, placebo-controlled trial. At 18.6 months, in patients with HRR alternations, the risk of progression or death was reduced by 27%. In patients with BRCA1/2 gene mutations, the risk of progression or death was reduced by 47%.

Erleada

Janssen announced real-world evidence data of Erleada (apalutamide), demonstrating that most patients achieved PSA90 response after six months of treatment. After six months of treatment, 69.3% of patients on Erleada achieved PSA90 response, 55.6% of patients on enzalutamide achieved PSA90 response. After nine months, 70.4% of patients on Erleada and 62.5% on enzalutamide achieved PSA90 response.

The company also announced Phase 3 SPARTAN and TITAN studies, where PSA90 response showed improvement in quality of life, physical well-being, pain, and fatigue.

MERCK

Lynparza plus abiraterone acetate

Merck announced the Phase 3 trial results of Lynparza (olaparib) plus abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene alterations.

PROpel study is a Phase 3 trial in which Lynparza met the primary endpoint. The risk of progression or death was decreased by 34% compared to placebo plus abiraterone acetate combination. Radiographic progression-free survival (rPFS) was 24.8 months in Lynparza + abiraterone arm versus 16.6 months in the placebo plus abiraterone arm. There was no statistically significant difference in the overall survival at the analysis time.


BMS

Opdivo + Cabometyx

Bristol Myers Squibb and Exelixis, Inc. announced two-year results of the Phase 3 CheckMate -9ER trial.

Opdivo (nivolumab) and Cabometyx (cabozantinib) combination resulted in the sustained survival rate health-related quality of life improvements, compared to sunitinib in patients with renal cell carcinoma as first-line therapy.

The risk of death was reduced by 30% in Opdivo + Cabometyx arm compared to sunitinib.

Median progression-free survival was 16.6 months in Opdivo + Cabometyx arm vs. 8.3 months in patients on sunitinib.

12.4 showed complete response in the combination arm versus 5.2% in patients on sunitinib.


BAYER

Darolutamide

Bayer presented the Phase III ARASENS trial of Nubeqa (darolutamide) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

The combination of darolutamide plus androgen deprivation therapy and docetaxel improved overall survival by 32% compared to androgen deprivation therapy and docetaxel.



 

Follow us on twitter and LinkedIn for latest pharmaceutical and healthcare news

 

For pipeline, market overview, and market access reports (syndicate and customized) please write to sales@firstviewinsight.com

For all syndicate reports: Click here

 




0 comments